SCHEMBL15846705

SCHEMBL15846705

COc1ncccc1-c1cc(O)c2nc[nH]c(=O)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 1/20 0.53
ACVR1 Q04771 2/20 0.43
BCL2 P10415 1/20 0.43
MCL1 Q07820 1/20 0.43
BTK Q06187 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
METAP2 P50579 2/20 0.40
DHODH Q02127 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.38
PARP1 P09874 2/20 0.37
ALOX5AP P20292 1/20 0.37
FEN1 P39748 1/20 0.37
BRD4 O60885 1/20 0.37
APLNR P35414 1/20 0.37
IDO1 P14902 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
ABL1 P00519 1/20 0.36
KDM4E B2RXH2 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15845828 0.84 IP6K1 (0.56) IP6K1ACVR1BCL2MCL1METAP2
SCHEMBL15846014 0.84 IP6K1 (0.55) IP6K1ACVR1BCL2MCL1BTK
SCHEMBL15846029 0.84 IP6K1 (0.46) IP6K1ACVR1BCL2MCL1METAP2
SCHEMBL15845607 0.83 IP6K1 (0.55) IP6K1BCL2MCL1PARP1BRD4
SCHEMBL15859719 0.83 IP6K1 (0.50) IP6K1ACVR1BCL2MCL1PARP1
SCHEMBL15846069 0.81 IP6K1 (0.55) IP6K1ACVR1BCL2MCL1BTK
SCHEMBL15845664 0.79 IP6K1 (0.58) IP6K1ACVR1BCL2MCL1BTK
SCHEMBL15846403 0.79 IP6K1 (0.60) IP6K1ACVR1BCL2MCL1BTK
SCHEMBL15845738 0.78 QPCT (0.49) IP6K1ACVR1BCL2MCL1METAP2
SCHEMBL15846044 0.78 IP6K1 (0.52) IP6K1ACVR1BCL2MCL1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US claimed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 EP claimed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US claimed
EP-2938600-A1 COMT INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-04 EP claimed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 WO claimed
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US disclosed
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US disclosed
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 EP disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 EP disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US disclosed
EP-2938600-A1 COMT INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-04 EP disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 WO disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002177-A1 COMT INHIBITORS COMT, PNMT, SLC6A3 IP6K1 4247/4885ACVR1 4796/4885BCL2 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.